Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

What We're Reading

  • What We're Reading
    A Sampling of Highlights from the Literature
    Cancer Immunol Res January 1 2021 9 (1) 1-1;

Cancer Immunology at the Crossroads

  • Cancer Immunology at the Crossroads
    Lighting a Fire: Can We Harness Pyroptosis to Ignite Antitumor Immunity?
    Zhibin Zhang, Ying Zhang and Judy Lieberman
    Cancer Immunol Res January 1 2021 9 (1) 2-7; DOI:10.1158/2326-6066.CIR-20-0525

Research Articles

  • Research Articles
    The Prognostic Role of Macrophage Polarization in the Colorectal Cancer Microenvironment
    Juha P. Väyrynen, Koichiro Haruki, Mai Chan Lau, Sara A. Väyrynen, Rong Zhong, Andressa Dias Costa, Jennifer Borowsky, Melissa Zhao, Kenji Fujiyoshi, Kota Arima, Tyler S. Twombly, Junko Kishikawa, Simeng Gu, Saina Aminmozaffari, Shanshan Shi, Yoshifumi Baba, Naohiko Akimoto, Tomotaka Ugai, Annacarolina Da Silva, Jennifer L. Guerriero, Mingyang Song, Kana Wu, Andrew T. Chan, Reiko Nishihara, Charles S. Fuchs, Jeffrey A. Meyerhardt, Marios Giannakis, Shuji Ogino and Jonathan A. Nowak
    Cancer Immunol Res January 1 2021 9 (1) 8-19; DOI:10.1158/2326-6066.CIR-20-0527

    Macrophage polarization state, rather than overall density, in the colorectal cancer microenvironment is associated with cancer-specific survival independent of potential confounding factors, with M1-like and M2-like macrophage phenotypes exhibiting distinct prognostic roles.

  • Research Articles
    Retinoic Acid Synthesis Deficiency Fosters the Generation of Polymorphonuclear Myeloid-Derived Suppressor Cells in Colorectal Cancer
    Hong-Wei Sun, Jing Chen, Wen-Chao Wu, Yan-Yan Yang, Yi-Tuo Xu, Xing-Juan Yu, Hai-Tian Chen, Zilian Wang, Xiao-Jun Wu and Limin Zheng
    Cancer Immunol Res January 1 2021 9 (1) 20-33; DOI:10.1158/2326-6066.CIR-20-0389

    A defect in ADH1-mediated retinoic acid synthesis contributes to the accumulation of polymorphonuclear (PMN)-MDSCs in colorectal cancer. The data highlight how restoring retinoic acid signaling could abrogate the generation of PMN-MDSCs and improve antitumor responses.

  • Research Articles | AuthorChoice
    A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy
    Si-Qi Liu, Alyssa Grantham, Casey Landry, Brian Granda, Rajiv Chopra, Srinivas Chakravarthy, Sabine Deutsch, Markus Vogel, Katie Russo, Katherine Seiss, William R. Tschantz, Tomas Rejtar, David A. Ruddy, Tiancen Hu, Kimberly Aardalen, Joel P. Wagner, Glenn Dranoff and Joseph A. D'Alessio
    Cancer Immunol Res January 1 2021 9 (1) 34-49; DOI:10.1158/2326-6066.CIR-20-0080

    A genome-wide CRISPR screen was developed to understand cancer cell–derived resistance mechanisms to CD3-bispecific antibodies. The screen identifies IFNγ signaling being pivotal for responsiveness to CD3 bispecifics, and deficiency in core fucosylation as causing resistance to the therapeutic flotetuzumab.

  • Research Articles
    A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies
    Iris de Weerdt, Roeland Lameris, George L. Scheffer, Jana Vree, Renate de Boer, Anita G. Stam, Rieneke van de Ven, Mark-David Levin, Steven T. Pals, Rob C. Roovers, Paul W.H.I. Parren, Tanja D. de Gruijl, Arnon P. Kater and Hans J. van der Vliet
    Cancer Immunol Res January 1 2021 9 (1) 50-61; DOI:10.1158/2326-6066.CIR-20-0138

    The generation of a CD40-specific Vγ9Vδ2 T-cell engager, which abrogates prosurvival CD40 signaling, is described. This bispecific antibody unleashes Vγ9Vδ2 T cell–mediated responses against both leukemia and multiple myeloma in vitro and in vivo.

  • Research Articles | AuthorChoice
    CD28 Costimulatory Domain–Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function
    Justin C. Boucher, Gongbo Li, Hiroshi Kotani, Maria L. Cabral, Dylan Morrissey, Sae Bom Lee, Kristen Spitler, Nolan J. Beatty, Estelle V. Cervantes, Bishwas Shrestha, Bin Yu, Aslamuzzaman Kazi, Xuefeng Wang, Said M. Sebti and Marco L. Davila
    Cancer Immunol Res January 1 2021 9 (1) 62-74; DOI:10.1158/2326-6066.CIR-20-0253

    CD28 mutations enhance CAR T-cell function by reducing expression of transcription factors such as NFAT and NUR77, which in turn reduce expression of exhaustion-related genes. These data highlight considerations for CAR design that could improve antitumor responses.

  • Research Articles | AuthorChoice
    The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
    Xiuli Wang, Christian Huynh, Ryan Urak, Lihong Weng, Miriam Walter, Laura Lim, Vibhuti Vyas, Wen-Chung Chang, Brenda Aguilar, Alfonso Brito, Aniee Sarkissian, N. Achini Bandara, Lu Yang, Jinhui Wang, Xiwei Wu, Jianying Zhang, Saul J. Priceman, Hong Qin, Larry W. Kwak, Lihua E. Budde, Sandra H. Thomas, Mary C. Clark, Leslie Popplewell, Tanya Siddiqi, Christine E. Brown and Stephen J. Forman
    Cancer Immunol Res January 1 2021 9 (1) 75-88; DOI:10.1158/2326-6066.CIR-20-0236

    In the clinic, CD19-CAR T cells are administered IV and are not used specifically to treat CNS lymphoma. The authors show a single ICV infusion of CD19-CAR T cells completely eradicates both CNS and systemic lymphoma in mice.

  • Research Articles
    Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
    Mara De Martino, Camille Daviaud, Julie M. Diamond, Jeffrey Kraynak, Amandine Alard, Silvia C. Formenti, Lance D. Miller, Sandra Demaria and Claire Vanpouille-Box
    Cancer Immunol Res January 1 2021 9 (1) 89-102; DOI:10.1158/2326-6066.CIR-19-0305

    Activin A and TGFβ can shape the breast cancer tumor microenvironment after radiotherapy. Dual blockade of activin A and TGFβ reverses radiotherapy-induced Treg increases and boosts antitumor responses, highlighting potential targetable factors for breast cancer treatment.

  • Research Articles
    Improved T-cell Receptor Diversity Estimates Associate with Survival and Response to Anti–PD-1 Therapy
    Dante S. Bortone, Mark G. Woodcock, Joel S. Parker and Benjamin G. Vincent
    Cancer Immunol Res January 1 2021 9 (1) 103-112; DOI:10.1158/2326-6066.CIR-20-0398

    Inaccurate TCR diversity estimates from RNA sequencing data have made the relationship between diversity and immunotherapy responses unclear. Improved estimation of diversity uncovers the association between diversity and responses of melanoma patients treated with PD-1 inhibition.

  • Research Articles
    Sialylation of CD55 by ST3GAL1 Facilitates Immune Evasion in Cancer
    Wen-Der Lin, Tan-Chi Fan, Jung‐Tung Hung, Hui-Ling Yeo, Sheng-Hung Wang, Chu-Wei Kuo, Kay-Hooi Khoo, Li-Mei Pai, John Yu and Alice L. Yu
    Cancer Immunol Res January 1 2021 9 (1) 113-122; DOI:10.1158/2326-6066.CIR-20-0203

    Silencing of the ST3GAL1 glycosyltransferase in breast cancer cells reduces O-sialylation of CD55, enhancing C3 deposition and susceptibility to complement- and antibody-dependent cytotoxicity. These findings suggest ST3GAL1 inhibition could be a strategy to block breast cancer immune evasion.

Acknowledgment to Reviewers

  • Acknowledgment to Reviewers | Free Article
    Acknowledgment to Reviewers
    Cancer Immunol Res January 1 2021 9 (1) 123-125; DOI:10.1158/2326-6066.CIR-9-1-Reviewers

Back to top
Previous
Cancer Immunology Research: 9 (1)
January 2021
Volume 9, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • What We're Reading
  • Cancer Immunology at the Crossroads
  • Research Articles
  • Acknowledgment to Reviewers
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • PD-L1 in Triple-Negative Breast Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement